A strong beat on the quarterly bottom line has helped Raymond James analyst Rahul Sarugaser stay positive on bioengineering company Ginkgo Bioworks (Ginkgo Bioworks Stock Quote, Chart, News NYSE:DNA), maintaining his “Outperform 2” rating and target price of $11.50/share in an update to clients on May 17. Boston-based Ginkgo Bioworks Holdings builds bespoke living cells through the […]
Strong earnings growth in its latest quarter has Haywood Capital Markets analyst Neal Gilmer staying bullish on 4Front Ventures (4Front Ventures Stock Quote, Chart, News CSE:FFNT). Gilmer maintained a “Buy” rating and C$1.50/share target price for a projected return of 67 per cent in an update to clients on Tuesday. Phoenix-based 4Front Ventures owns and manages […]
Share
Tweet
Share
